> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron’s Dupixent Approved for Asthma
- URL: https://www.fdaweb.com/regenerons-dupixent-approved-for-asthma/
- Published: 2018-10-22T12:00:00.000Z
- Updated: 2026-09-15T00:39:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142642

FDA has approved Regeneron’s Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent works by inhibiting the overactive signaling of interleukin-4 and interleukin-13, two key proteins that contribute to the Type 2 inflammation that may underlie moderate-to-severe asthma, the company says. Dupixent was originally approved in 2017 for treating adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.